Introduction
Hydrogest DS IM Injection is used to prevent premature labor in pregnant women in order to reduce the risk of giving birth too early (preterm birth). It prevents miscarriage and lower the risk of premature birth in women who have had one premature delivery in the past.
Hydrogest DS IM Injection is administered only by or under the supervision of doctor. It should be taken as your doctor advice. Your doctor will decide how much you need to take and for how much time. You should take this injection for as long as it is prescribed for you.
The most common side effects of this medicine include local site reactions at injection site, nausea, itching, diarrhea, and hives. If any of these bothers you, let your doctor know. There may be ways of reducing or preventing them. It may affect blood sugar levels, so monitor your blood sugar regularly. It is better to inform the doctor if you notice yellowing of eyes or skin, dark urine, or stomach pain while using this medicine.
Before taking this medicine inform doctor, if you have ever had any problems with your blood circulation or have diabetes, or any liver disease. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works.
Uses of Hydrogest DS IM Injection
Side effects of Hydrogest DS IM Injection
Common
- Nausea
- Itching
- Diarrhea
- Hives
- Nodules
How to use Hydrogest DS IM Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Hydrogest DS IM Injection works
Hydrogest DS IM Injection is a progestin (female hormone). It works by modulating the immune response of the mother to prevent rejection of the embryo and allow its attachment to the uterus. This prevents miscarriage and helps lower the risk of premature birth in women who have had one premature delivery in the past.
Indication
Preterm Labor, Recurrent miscarriage, Amenorrhoea, Abnormal uterine bleeding, Palliative treatment of advanced, inoperable endometrial carcinoma
Administration
IM Administration
Inject IM over 1 minute in upper outer quadrant of the gluteus maximus
Inject IM over 1 minute in upper outer quadrant of the gluteus maximus The solution if viscous and oilyThe solution if viscous and oily
1-mL vial does not contain preservatives and is for single dose use
Once opened, the 5-mL multidose vial must be used within 5 weeks
Adult Dose
Intramuscular
Preterm Labor
Indicated for prevention of preterm labor in a singleton pregnancy for patients aged 16 years or older who have a history of spontaneous preterm birth
250 mg IM qWeek
Initiate between the 16th and 20th week of gestation and ending at the 37th week of gestation or birth (whichever is first)
Recurrent miscarriage
Adult: 250-500 mg wkly during the 1st half of pregnancy.
Amenorrhoea; Abnormal uterine bleeding
Adult: Single dose of 375 mg; may repeat at 4-wkly intervals if needed. After 4 days of desquamation, or if there is no bleeding within 21 days after admin of the drug, may initiate cyclic therapy that includes an oestrogen. For cyclic treatment (28-day cycle): Administer 20 mg of estradiol valerate on day 1, and on day 15, administer 250 mg of hydroxyprogesterone caproate and 5 mg of estradiol valerate. May repeat cyclic therapy at 4-wkly intervals as needed.
Palliative treatment of advanced, inoperable endometrial carcinoma
Adult: Usual dose: ?1 g, may repeat once or more times wkly. Usual range: 1-7 g/wk. Discontinue treatment if relapse occurs or if the objective response is not achieved after 12 wk of treatment.
Hepatic Impairment
Not studied; product is extensively metabolized in liver; potential for reduce elimination
Child Dose
Safety and efficacy not established
Renal Dose
Not studied in patients with renal impairment
Contraindication
Undiagnosed vaginal bleeding, breast cancer, pregnancy, lactation. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy or a history of these conditions. Markedly impaired liver function.
Mode of Action
Hydroxyprogesterone caproate stimulates luteal actions, changes in uterus and vagina as seen in early pregnancy. It also has prolonged uterotrophic effect. Contractile response of the myometrium to oxytocin is inhibited.
Precaution
Physical examination is advised prior to starting therapy. Hepatic impairment, mental depression. Monitor blood glucose in diabetic patients. Discontinue treatment upon signs of thromboembolic and thrombotic disorders. Discontinue treatment if unexplained, sudden or gradual, partial or complete loss of vision, protopsis, diplopia or papilledema, retinal vascular lesions or migraine occur. Caution when used in patients with conditions that might be worsened by fluid retention (e.g. asthma, seizure disorders, migraine, cardiac or renal dysfunction).
Pregnancy Category Note
No adequate or well-controlled studies in women during first trimester
Interaction
Increased clearance when used with enzyme inducers e.g. carbamazepine and phenytoin. May inhibit metabolism of ciclosporin.